Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia

被引：3

作者：

Li, Xueyao ^{[1
]}

Tong, Xiuzhen ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, 58 Second Zhongshan Rd, Guangzhou 510080, Peoples R China

来源：

CLINICAL INTERVENTIONS IN AGING | 2023年 / 18卷

关键词：

detection method; risk-stratification marker; postremission decisions; personalized medicine; HEMATOPOIETIC-CELL TRANSPLANTATION; CLONAL HEMATOPOIESIS; PROGNOSTIC RELEVANCE; AML; MUTATIONS; AZACITIDINE; THERAPY; RISK; DECITABINE; MANAGEMENT;

D O I：

10.2147/CIA.S409308

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

There is overwhelming evidence indicating that the use of measurable residual disease (MRD) as a biomarker provides critical prognostic information and that MRD may have a role in directing postremission decisions. There are a variety of assays for MRD assessment, such as multiparameter flow cytometry and molecular assessment of MRD, which present different characteristics in patients older than 60 years of age. Due to multiple reasons related to age, the progress of older adult AML patients is rarely investigated, especially with respect to MRD. In this review, we will clarify the characteristics of different assays for assessing MRD, focusing on its role as a risk-stratification biomarker to predict prognostic information and its role in optimal postremission therapy among older adult AML patients. These characteristics also provide guidance regarding the potential to apply personalized medicine in older adult AML patients.

引用

页码：921 / 931

页数：11

共 50 条

[21] Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns [J].

Bozic, Tanja ;

Kuo, Chao-Chung ;

Hapala, Jan ;

Franzen, Julia ;

Eipel, Monika ;

Platzbecker, Uwe ;

Kirschner, Martin ;

Beier, Fabian ;

Jost, Edgar ;

Thiede, Christian ;

Wagner, Wolfgang .

LEUKEMIA, 2022, 36 (01) :80-89

[22] Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia [J].

Gui, Gege ;

Hourigan, Christopher S. .

CANCER JOURNAL, 2022, 28 (01) :73-77

[23] Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling [J].

Ganzel, Chezi ;

Sun, Zhuoxin ;

Baslan, Timour ;

Zhang, Yanming ;

Gonen, Mithat ;

Abdel-Wahab, Omar, I ;

Racevskis, Janis ;

Garrett-Bakelman, Francine ;

Lowe, Scott W. ;

Fernandez, Hugo F. ;

Ketterling, Rhett ;

Luger, Selina M. ;

Litzow, Mark ;

Lazarus, Hillard M. ;

Rowe, Jacob M. ;

Tallman, Martin S. ;

Levine, Ross L. ;

Paietta, Elisabeth .

LEUKEMIA RESEARCH, 2022, 123

[24] Flow cytometric measurable residual disease in adult acute myeloid leukemia: a preliminary report from Eastern India [J].

Singh, Neha ;

Gupta, Avinash ;

Kumar, Sujeet ;

Mawalankar, Gojiri ;

Gupta, Bhumika ;

Dhole, Nilesh ;

Kori, RohitKumar ;

Singh, Anil .

JOURNAL OF HEMATOPATHOLOGY, 2023, 16 (01) :17-25

[25] Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia [J].

Hasserjian, Robert P. ;

Steensma, David P. ;

Graubert, Timothy A. ;

Ebert, Benjamin L. .

BLOOD, 2020, 135 (20) :1729-1738

[26] Widespread use of measurable residual disease in acute myeloid leukemia practice [J].

Epstein-Peterson, Zachary D. ;

Devlin, Sean M. ;

Stein, Eytan M. ;

Estey, Elihu ;

Tallman, Martin S. .

LEUKEMIA RESEARCH, 2018, 67 :92-98

[27] Measurable residual disease in pediatric acute myeloid leukemia: a systematic review [J].

Segerink, W. H. ;

de Haas, V ;

Kaspers, G. J. L. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) :451-459

[28] Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine [J].

Pratz, Keith W. ;

Jonas, Brian A. ;

Pullarkat, Vinod ;

Recher, Christian ;

Schuh, Andre C. ;

Thirman, Michael J. ;

Garcia, Jacqueline S. ;

DiNardo, Courtney D. ;

Vorobyev, Vladimir ;

Fracchiolla, Nicola S. ;

Yeh, Su-Peng ;

Jang, Jun Ho ;

Ozcan, Muhit ;

Yamamoto, Kazuhito ;

Illes, Arpad ;

Zhou, Ying ;

Dail, Monique ;

Chyla, Brenda ;

Potluri, Jalaja ;

Doehner, Hartmut .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (08) :855-+

[29] Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia [J].

Dillon, Laura W. ;

Higgins, Jake ;

Nasif, Hassan ;

Othus, Megan ;

Beppu, Lan ;

Smith, Thomas H. ;

Schmidt, Elizabeth ;

Valentine III, Charles C. ;

Salk, Jesse J. ;

Wood, Brent L. ;

Erba, Harry P. ;

Radich, Jerald P. ;

Hourigan, Christopher S. .

HAEMATOLOGICA, 2024, 109 (02) :401-410

[30] Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation [J].

Srour, Samer A. ;

Saliba, Rima M. ;

Bittencourt, Maria C. B. ;

Perez, Jorge M. R. ;

Kongtim, Piyanuch ;

Alousi, Amin ;

Al-Atrash, Gheath ;

Olson, Amanda ;

Betul, Oran ;

Mehta, Rohtesh ;

Popat, Uday ;

Hosing, Chitra ;

Bashir, Qaiser ;

Khouri, Issa ;

Kebriaei, Partow ;

Masarova, Lucia ;

Short, Nicholas ;

Jabbour, Elias ;

Daver, Naval ;

Konopleva, Marina ;

Ravandi, Farhad ;

Kantarjian, Hagop ;

Champlin, Richard E. ;

Ciurea, Stefan O. .

AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) :1382-1387

← 1 2 3 4 5 →